- Home
- SIDU vs BCDA Comparison
SIDU vs BCDA Comparison
Compare SIDU & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIDU
- BCDA
- Stock Information
- Founded
- SIDU 2012
- BCDA N/A
- Country
- SIDU United States
- BCDA United States
- Employees
- SIDU N/A
- BCDA N/A
- Industry
- SIDU Telecommunications Equipment
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- SIDU Telecommunications
- BCDA Health Care
- Exchange
- SIDU Nasdaq
- BCDA Nasdaq
- Market Cap
- SIDU 10.3M
- BCDA 7.9M
- IPO Year
- SIDU 2021
- BCDA N/A
- Fundamental
- Price
- SIDU $2.47
- BCDA $2.60
- Analyst Decision
- SIDU Strong Buy
- BCDA Strong Buy
- Analyst Count
- SIDU 1
- BCDA 1
- Target Price
- SIDU $10.00
- BCDA $25.00
- AVG Volume (30 Days)
- SIDU 363.4K
- BCDA 74.1K
- Earning Date
- SIDU 11-12-2024
- BCDA 11-06-2024
- Dividend Yield
- SIDU N/A
- BCDA N/A
- EPS Growth
- SIDU N/A
- BCDA N/A
- EPS
- SIDU N/A
- BCDA N/A
- Revenue
- SIDU $4,306,474.00
- BCDA $428,000.00
- Revenue This Year
- SIDU $36.85
- BCDA $6.92
- Revenue Next Year
- SIDU $40.00
- BCDA N/A
- P/E Ratio
- SIDU N/A
- BCDA N/A
- Revenue Growth
- SIDU N/A
- BCDA 0.71
- 52 Week Low
- SIDU $2.02
- BCDA $1.96
- 52 Week High
- SIDU $18.85
- BCDA $23.25
- Technical
- Relative Strength Index (RSI)
- SIDU 44.54
- BCDA 46.60
- Support Level
- SIDU $2.14
- BCDA $2.39
- Resistance Level
- SIDU $2.53
- BCDA $2.84
- Average True Range (ATR)
- SIDU 0.20
- BCDA 0.17
- MACD
- SIDU -0.01
- BCDA -0.00
- Stochastic Oscillator
- SIDU 42.40
- BCDA 41.18
About SIDU Sidus Space Inc.
Sidus Space Inc is a Space and Defense as-a-Service company focused on providing complex space hardware, satellite/spacecraft design, manufacture, launch, and data solutions for both government and commercial in-space missions for all destinations through the solar system. This includes a Space-based infrastructure of multi-mission satellites with hyperspectral, multi-spectral, and other sensors to provide monitoring services and solutions to multiple sectors and industries. The company supports Commercial Space, Aerospace, Defense, Underwater Marine, and other commercial and government customers.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).